Titan amends Braeburn's Probuphine license, adopts poison pill
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticals has 13 months to win US FDA approval for its opioid dependence therapy Probuphine (buprenorphine hydrochloride) delivered via subdermal implant under an amended license agreement with Braeburn Pharmaceuticals, which doesn't give the company much time to address concerns raised in the FDA's recent rejection of the drug.